Skip to main content
OpenTrials
Completed

NCT Number: NCT04364867

Exparel for Total Shoulder Arthroplasty

The primary objective of this study is to determine if Exparel leads to better pain scores at 24, 48 and 72 hours after Total Shoulder Arthroplasty (TSA) compared to a pain pump. Secondary objectives are (1) to determine if patients on Exparel use less narcotics and (2) have earlier return of functional use of the involved arm after surgery compared to the pain pump and (3) if use of Exparel leads to cost savings

METHODS

Sample size:

Based on prior studies on anesthetics for TSA, the mean worst pain score in the 24 hours after surgery was 5.4, based on a 0 to 10 scale. To detect a change of 2 points, alpha of 0.05, beta of 0.80, a sample size of 51 subjects in each group will be required. To account for drop-outs, a total of 60 subjects in each arm will be enrolled.

Inclusion criteria Patients undergoing unilateral primary TSA or reverse TSA Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears Surgery performed by the Principal Investigator Anesthesia administered by Co-Principal Investigator Willing and able to sign an Informed Consent Exclusion criteria Indication for surgery is fracture Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia) Has hepatic disease On workers compensation/disability/litigation Known adverse reaction to medications to be administered On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone) Home Oxygen requirement whether as needed or scheduled. Contralateral Phrenic Nerve paralysis / incompetence. Body Mass Index ≥ 50 Randomization will be a varied blocked randomization with blocks of 12, 15 and 18 using sealed envelopes

Treatment arms:

Control: Pain catheter based pain control. Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.

Interventional: Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Both arms will receive the same multimodal analgesia medications preoperatively. Celebrex 400mg PO, Gabapentin 600mg PO, Tylenol 1 gram PO, unless contraindicated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Norton Healthcare

Louisville, Kentucky, 40202, United States

About this study

The primary objective of this study is to determine if Exparel leads to better pain scores at 24, 48 and 73 hours after TSA compared to a pain pump. Secondary objectives are (1) to determine if patients on Exparel use less narcotics and (2) have earlier return of functional use of the involved arm after surgery compared to the pain pump and (3) if use of Exparel leads to cost savings

METHODS

Sample size:

Based on prior studies on anesthetics for TSA, the mean worst pain score in the 24 hours after surgery was 5.4, based on a 0 to 10 scale. To detect a change of 2 points, alpha of 0.05, beta of 0.80, a sample size of 51 subjects in each group will be required. To account for drop-outs, a total of 60 subjects in each arm will be enrolled.

Inclusion criteria

Patients undergoing unilateral primary TSA or reverse TSA Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears Surgery performed by the Principal Investigator Anesthesia administered by Co-Principal Investigator Willing and able to sign an Informed Consent Exclusion criteria Indication for surgery is fracture Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia) Has hepatic disease On workers compensation/disability/litigation Known adverse reaction to medications to be administered On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone) Home Oxygen requirement whether as needed or scheduled. Contralateral Phrenic Nerve paralysis / incompetence. Body Mass Index ≥ 50 Randomization will be a varied blocked randomization with blocks of 12, 15 and 18 using sealed envelopes

Treatment arms:

Control: Pain catheter based pain control. Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.

Interventional: Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Both arms will receive the same multimodal analgesia medications preoperatively. Celebrex 400mg PO, Gabapentin 600mg PO, Tylenol 1 gram PO, unless contraindicated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing unilateral primary TSA or reverse TSA
  • Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears
  • Surgery performed by the Principal Investigator
  • Anesthesia administered by Co-Principal Investigator
  • Willing and able to sign an Informed Consent

Exclusion criteria

  • Indication for surgery is fracture
  • Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression
  • Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia)
  • Has hepatic disease
  • On workers compensation/disability/litigation
  • Known adverse reaction to medications to be administered
  • On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone)
  • Home Oxygen requirement whether as needed or scheduled.
  • Contralateral Phrenic Nerve paralysis / incompetence.
  • Body Mass Index ≥ 50

Treatment and study plan

Exparel

Drug

Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Pain Pump

Drug

Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.

Primary outcomes

  1. Pain Score in the 24 Hours After Surgery

    Time frame: 24 hours after surgery

    Worst pain score (0 [none] to 10 [worst possible]) in the 24 hours after surgery

Secondary outcomes

  1. Pain Score in the 48 Hours After Surgery

    Time frame: 48 hours

    Worst pain score (0 [none] to 10 [worst possible]) in the 48 hours after surgery

  2. Cumulative Morphine Milligram Equivalents at 24 Hours

    Time frame: 24 hours

    Cumulative Morphine Milligram Equivalents consumed at 24 hours

  3. Cumulative Morphine Milligram Equivalents at 48 Hours

    Time frame: 48 hours

    Cumulative Morphine Milligram Equivalents consumed at 48 hours

  4. Cumulative Morphine Milligram Equivalents at 72 Hours

    Time frame: 72hours

    Cumulative Morphine Milligram Equivalents consumed at 72 hours

  5. Pain Score in the 72 Hours After Surgery

    Time frame: 72 hours

    Worst pain score (0 [none] to 10 [worst possible]) in the 72 hours after surgery

Sponsors and collaborators

Lead sponsor

Norton Healthcare

Other

Registry information

Official study title

Randomized Clinical Trial of Exparel vs Pain Pump for Post-operative Pain Control After Total Shoulder Arthroplasty

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Apr 28, 2020
Registry last updated
Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.